TAOX

Company Overview — What Does Synaptogenix, Inc. Do?

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. Synaptogenix, Inc. (TAOX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alan J. Tuchman and employs approximately 4 people. With a market capitalization of $43M, TAOX is one of the notable companies in the Healthcare sector.

Synaptogenix, Inc. (TAOX) Stock Rating — Reduce (April 2026)

As of April 2026, Synaptogenix, Inc. receives a Reduce rating with a composite score of 30.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TAOX ranks #2,356 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Synaptogenix, Inc. ranks #285 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TAOX Stock Price and 52-Week Range

Synaptogenix, Inc. (TAOX) currently trades at $4.24. The stock lost $0.80 (15.9%) in the most recent trading session. The 52-week high for TAOX is $11.98, which means the stock is currently trading -64.6% from its annual peak. The 52-week low is $1.84, putting the stock 130.4% above its annual trough. Recent trading volume was 1.0M shares, reflecting moderate market activity.

Is TAOX Overvalued or Undervalued? — Valuation Analysis

Synaptogenix, Inc. (TAOX) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.57x, versus the sector average of 2.75x. The price-to-sales ratio is 198.93x, compared to 1.66x for the average Healthcare stock.

At current multiples, Synaptogenix, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Synaptogenix, Inc. Profitability — ROE, Margins, and Quality Score

Synaptogenix, Inc. (TAOX) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -166.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -146.0% versus the sector average of -33.1%.

On a margin basis, Synaptogenix, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -38754.3% (sector: -66.1%). Net profit margin stands at -222015.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TAOX Debt, Balance Sheet, and Financial Health

Synaptogenix, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 17.61x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $0.

TAOX has a beta of 1.83, meaning it is more volatile than the broader market — a $10,000 investment in TAOX would be expected to move 82.7% more than the S&P 500 on any given day. The stability factor score for Synaptogenix, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Synaptogenix, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Synaptogenix, Inc. reported revenue of $207,333 and earnings per share (EPS) of $-1.56. Net income for the quarter was $-27M. Gross margin was 100.0%. Operating income came in at $-7M.

In Q3 2025, Synaptogenix, Inc. reported revenue of $203,371 and earnings per share (EPS) of $-1.56. Net income for the quarter was $-4M. Operating income came in at $-2M.

In Q2 2025, Synaptogenix, Inc. reported revenue of $3,962 and earnings per share (EPS) of $-11.26. Net income for the quarter was $-18M. Gross margin was 100.0%. Operating income came in at $-3M.

In Q1 2025, Synaptogenix, Inc. reported revenue of $0 and earnings per share (EPS) of $0.12. Net income for the quarter was $385,169. Operating income came in at $-1M.

Over the past 8 quarters, Synaptogenix, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $207,333. Investors analyzing TAOX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TAOX Dividend Yield and Income Analysis

Synaptogenix, Inc. (TAOX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TAOX Momentum and Technical Analysis Profile

Synaptogenix, Inc. (TAOX) has a momentum factor score of 57/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

TAOX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Synaptogenix, Inc. (TAOX) ranks #285 out of 838 stocks based on the Blank Capital composite score. This places TAOX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TAOX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TAOX vs S&P 500 (SPY) comparison to assess how Synaptogenix, Inc. stacks up against the broader market across all factor dimensions.

TAOX Next Earnings Date

No upcoming earnings date has been announced for Synaptogenix, Inc. (TAOX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TAOX? — Investment Thesis Summary

The quantitative profile for Synaptogenix, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. High volatility (stability score 13/100) increases portfolio risk.

In summary, Synaptogenix, Inc. (TAOX) earns a Reduce rating with a composite score of 30.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TAOX stock.

Related Resources for TAOX Investors

Explore more research and tools: TAOX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TAOX head-to-head with peers: TAOX vs AZN, TAOX vs SLGL, TAOX vs VMD.